Role of X-linked inhibitor of apoptosis as a prognostic marker and therapeutic target in papillary thyroid carcinoma

Journal of Clinical Endocrinology and Metabolism

Volumn 100, Issue 7, 2015, Pages E974-E985

  Hussain, Azhar R ^a   Bu, Rong ^a   Ahmed, Maqbool ^a   Jehan, Zeenath ^a   Beg, Shaham ^a   Al Sobhi, Saif ^a   Al Dayel, Fouad ^a   Siraj, Abdul K ^a   Uddin, Shahab ^a   Al Kuraya, Khawla S ^a,b  

^a KING FAISAL SPECIALIST HOSPITAL AND RESEARCH CENTER   (Saudi Arabia)

^b ALFAISAL UNIVERSITY   (Saudi Arabia)

Author keywords

[No Author keywords available]

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; EMBELIN; KI 67 ANTIGEN; PROTEIN BCL XL; PROTEIN KINASE B; TUMOR MARKER; X LINKED INHIBITOR OF APOPTOSIS; ANTINEOPLASTIC AGENT; BENZOQUINONE DERIVATIVE; XIAP PROTEIN, HUMAN;

ADULT; ADVANCED CANCER; AGING; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CANCER LOCALIZATION; CANCER PROGNOSIS; CANCER REGRESSION; CANCER SIZE; CANCER STAGING; CANCER SURVIVAL; CARCINOMA CELL LINE; COHORT ANALYSIS; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE FREE SURVIVAL; DNA MICROARRAY; DRUG MECHANISM; DRUG POTENTIATION; ENZYME PHOSPHORYLATION; FEMALE; GENE DOSAGE; GENE FUNCTION; GENE IDENTIFICATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REFERENCE VALUE; THYROID CARCINOMA; TISSUE MICROARRAY; TUMOR XENOGRAFT; AGED; ANIMAL; ANTAGONISTS AND INHIBITORS; CARCINOMA; DRUG SCREENING; GENE EXPRESSION REGULATION; GENETICS; MIDDLE AGED; MOLECULARLY TARGETED THERAPY; MORTALITY; NUDE MOUSE; PATHOLOGY; PHYSIOLOGY; PROCEDURES; PROGNOSIS; THYROID NEOPLASMS; TUMOR CELL LINE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BENZOQUINONES; CARCINOMA; CELL LINE, TUMOR; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MICE; MICE, NUDE; MIDDLE AGED; MOLECULAR TARGETED THERAPY; PROGNOSIS; THYROID NEOPLASMS; TUMOR MARKERS, BIOLOGICAL; X-LINKED INHIBITOR OF APOPTOSIS PROTEIN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84944169486     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2014-4356     Document Type: Article

References (40)

1. Nikiforov YE. Thyroid carcinoma: molecular pathways and therapeutic targets. Mod Pathol. 2008;2(suppl 21):S37-S43.
2. Al-Hamdan N, Ravichandran K, Al-Sayyad J, et al. Incidence of cancer in Gulf Cooperation Council countries, 1998-2001. East Mediterr Health J. 2009;15:600-611.
3. Nixon IJ, Ganly I, Patel SG, et al. Changing trends in well differentiated thyroid carcinoma over eight decades. Int J Surg. 2012;10: 618-623.
4. Davies L, Welch HG. Increasing incidence of thyroid cancer in the United States, 1973-2002. JAMA. 2006;295:2164-2167.
5. Ito Y, Kudo T, Kihara M, et al. Improvement of lymph node recurrence rate, but not distant recurrence and carcinoma death rates, in patients with papillary thyroid carcinoma after disease-free survival for 5 years. Endocr J. 2012;59:895-901.
6. Durante C, Montesano T, Torlontano M, et al. Papillary thyroid cancer: time course of recurrences during postsurgery surveillance. J Clin Endocrinol Metab. 2013;98:636-642.
7. Lang BH, Tang AH, Wong KP, Shek TW, Wan KY, Lo CY. Significance of size of lymph node metastasis on postsurgical stimulated thyroglobulin levels after prophylactic unilateral central neck dissection in papillary thyroid carcinoma. Ann Surg Oncol. 2012;19: 3472-3478.
8. Moussata D, Amara S, Siddeek B, et al. XIAP as a radioresistance factor and prognostic marker for radiotherapy in human rectal adenocarcinoma. Am J Pathol. 2012;181:1271-1278.
9. Hussain AR, Uddin S, Ahmed M, et al. Prognostic significance of XIAP expression in DLBCL and effect of its inhibition on AKT signalling. J Pathol. 2010;222:180-190.
10. Eckelman BP, Salvesen GS, Scott FL. Human inhibitor of apoptosis proteins: why XIAP is the black sheep of the family. EMBO Rep. 2006;7:988-994.
11. Augello C, Caruso L, Maggioni M, et al. Inhibitors of apoptosis proteins (IAPs) expression and their prognostic significance in hepatocellular carcinoma. BMC Cancer. 2009;9:125.
12. Xiang G, Wen X, Wang H, Chen K, Liu H. Expression of X-linked inhibitor of apoptosis protein in human colorectal cancer and its correlation with prognosis. J Surg Oncol. 2009;100:708-712.
13. Dai Y, Qiao L, Chan KW, et al. Adenovirus-mediated down-regulation of X-linked inhibitor of apoptosis protein inhibits colon cancer. Mol Cancer Ther. 2009;8:2762-2770.
14. McKenna SL, Cotter TG. Functional aspects of apoptosis in hematopoiesis and consequences of failure. Adv Cancer Res. 1997;71: 121-164.
15. Mansilla S, Llovera L, Portugal J. Chemotherapeutic targeting of cell death pathways. Anticancer Agents Med Chem. 2012;12:226-238.
16. HengartnerMO. The biochemistry of apoptosis. Nature. 2000;407: 770-776.
17. Slee EA, Keogh SA, Martin SJ. Cleavage of BID during cytotoxic drug andUVradiation-induced apoptosis occurs downstream of the point of Bcl-2 action and is catalysed by caspase-3: a potential feedback loop for amplification of apoptosis-associated mitochondrial cytochrome c release. Cell Death Differ. 2000;7:556-565.
18. Castaneda CA, Cortes-Funes H, Gomez HL, Ciruelos EM. The phosphatidyl inositol 3-kinase/AKT signaling pathway in breast cancer. Cancer Metastasis Rev. 2010;29:751-759.
19. Agarwal E, BrattainMG,ChowdhuryS. Cell survival and metastasis regulation by Akt signaling in colorectal cancer. Cell Signal. 2013; 25:1711-1719.
20. Uddin S, Hussain AR, Siraj AK, et al. Role of phosphatidylinositol 3-kinase/AKT pathway in diffuse large B-cell lymphoma survival. Blood. 2006;108:4178-4186.
21. Asselin E, Mills GB, Tsang BK. XIAP regulates Akt activity and caspase-3-dependent cleavage during cisplatin-induced apoptosis in human ovarian epithelial cancer cells. Cancer Res. 2001;61:1862-1868.
22. Gagnon V, Van Themsche C, Turner S, Leblanc V, Asselin E. Akt and XIAP regulate the sensitivity of human uterine cancer cells to cisplatin, doxorubicin and taxol. Apoptosis. 2008;13:259-271.
23. Uddin S, Siraj AK, Al-RasheedM,et al. Fatty acid synthase andAKT pathway signaling in a subset of papillary thyroid cancers. J Clin Endocrinol Metab. 2008;93:4088-4097.
24. Siraj AK, Bavi P, Abubaker J, et al. Genome-wide expression analysis of Middle Eastern papillary thyroid cancer reveals c-MET as a novel target for cancer therapy. J Pathol. 2007;213:190-199.
25. Badve S, Turbin D, Thorat MA, et al. FOXA1 expression in breast cancer-correlation with luminal subtypeAand survival. Clin Cancer Res. 2007;13:4415-4421.
26. Camp RL, Dolled-Filhart M, Rimm DL. X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. Clin Cancer Res. 2004;10:7252-7259.
27. McCarthy MM, Sznol M, DiVito KA, Camp RL, Rimm DL, Kluger HM. Evaluating the expression and prognostic value of TRAIL-R1 and TRAIL-R2 in breast cancer. Clin Cancer Res. 2005;11:5188-5194.
28. Zhao M, Sano D, Pickering CR, et al. Assembly and initial characterization of a panel of 85 genomically validated cell lines from diverse head and neck tumor sites. Clin Cancer Res. 2011;17:7248-7264.
29. Uddin S, Hussain AR, Manogaran PS, et al. Curcumin suppresses growth and induces apoptosis in primary effusion lymphoma. Oncogene. 2005;24:7022-7030.
30. Hussain AR, Al-Jomah NA, Siraj AK, et al. Sanguinarine-dependent induction of apoptosis in primary effusion lymphoma cells. Cancer Res. 2007;67:3888-3897.
31. Uddin S, Hussain AR, Ahmed M, et al. Overexpression of FoxM1 offers a promising therapeutic target in diffuse large B-cell lymphoma. Haematologica. 2012;97:1092-1100.
32. Hussain AR, Ahmed M, Al-Jomah NA, et al. Curcumin suppresses constitutive activation of nuclear factor-B and requires functional Bax to induce apoptosis in Burkitt's lymphoma cell lines. Mol Cancer Ther. 2008;7:3318-3329.
33. Uddin S, Hussain A, Al-Hussein K, Platanias LC, Bhatia KG. Inhibition of phosphatidylinositol 3-kinase induces preferentially killing of PTEN-null T leukemias through AKT pathway. Biochem Biophys Res Commun. 2004;320:932-938.
34. Wu M, Sun K, Gil J, Gan L, Burstein DE. Immunohistochemical detection of p63 and XIAP in thymic hyperplasia and thymomas. Am J Clin Pathol. 2009;131:689-693.
35. Nagi C, Xiao GQ, Li G, Genden E, Burstein DE. Immunohistochemical detection of X-linked inhibitor of apoptosis in head and neck squamous cell carcinoma. Ann Diagn Pathol. 2007;11:402-406.
36. Gu LQ, Li FY, Zhao L, et al. BRAFV600E mutation and X-linked inhibitor of apoptosis expression in papillary thyroid carcinoma. Thyroid. 2009;19:347-354.
37. Yim JH, Yoon JH, Kim SA, et al. Expression of X-linked inhibitor of apoptosis protein in neoplastic thyroid disorder. J Korean Med Sci. 2011;26:1191-1195.
38. Xiao GQ, Unger PD, Burstein DE. Immunohistochemical detection of X-linked inhibitor of apoptosis (XIAP) in neoplastic and other thyroid disorders. Ann Diagn Pathol. 2007;11:235-240.
39. Yang S, Thor AD, Edgerton S, Yang X. Caspase-3 mediated feedback activation of apical caspases in doxorubicin and TNF-induced apoptosis. Apoptosis. 2006;11:1987-1997.
40. Ferreira KS, Kreutz C, Macnelly S, et al. Caspase-3 feeds back on caspase-8, Bid and XIAP in type I Fas signaling in primary mouse hepatocytes. Apoptosis. 2012;17:503-515.